science1 distinct publisher
The GSK-Pfizer merger did cut costs. A rival put prices up 8.55 percent anyway.
A study of Philippine cough and cold prices confirms real savings on Pfizer lines after the 2019 deal, then finds Sanofi, never a party to it, raised prices by more than Pfizer's fell.
Publishers:phys.org
Reality
- Evidence52
- Adoption24
- Hype gap+16
- Incentives58
- Confidence47